Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

16.980
+0.0400.24%
Volume:3.31M
Turnover:57.23M
Market Cap:18.02B
PE:-40.33
High:17.920
Open:17.200
Low:16.810
Close:16.940
52wk High:18.750
52wk Low:4.090
Shares:1.06B
HK Float Shares:1.06B
Volume Ratio:0.91
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.421
ROE:-18.45%
ROA:-14.45%
PB:8.19
PE(LYR):-40.33
PS:7809.44

Loading ...

China NMPA Accepts New Drug Application for Ascletis Pharma's Denifanstat for Acne Treatment

Reuters
·
Dec 10, 2025

Ascletis Pharma Inc - Nmpa Acceptance of Nda for Denifanstat

THOMSON REUTERS
·
Dec 10, 2025

Shares of Chinese Drugmaker Ascletis Rise on Weight-Loss Drug Results

Dow Jones
·
Dec 09, 2025

Citi: Ascletis-B's ASC30 Phase IIa Data Further Demonstrates Best-in-Class Potential, Reiterates "Buy/High Risk" Rating

Deep News
·
Dec 09, 2025

Hong Kong Stocks Narrowly Fluctuate; ASCLETIS-B Surges Over 23% on Positive News

Deep News
·
Dec 09, 2025

HK Movers | Biomedical Stocks Jump With Ascletis Pharma up 21%, Sirnaomics up 11%

Tiger Newspress
·
Dec 09, 2025

HK Movers | Ascletis Pharma Surges as ASC30 Shows Positive Top-Line Results in 13-Week Phase 2 Obesity Trial

Tiger Newspress
·
Dec 09, 2025

Ascletis Pharma Inc - Asc30 Tablets Show Significant Dose-Dependent Weight Reductions

THOMSON REUTERS
·
Dec 08, 2025

Ascletis' Oral Small Molecule Glp-1, Asc30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% With Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase Ii Study in Participants With Obesity or Overweight

THOMSON REUTERS
·
Dec 08, 2025

Ascletis Pharma Inc - No Hepatic Safety Signal Observed in Asc30 Study

THOMSON REUTERS
·
Dec 08, 2025

ASCLETIS-B (01672): Positive Topline Results from 13-Week Phase II Study of ASC30 for Obesity Treatment

Stock News
·
Dec 08, 2025

Ascletis Pharma Reports 7.7% Placebo-Adjusted Weight Loss With Oral GLP-1 Drug ASC30 in Phase II Obesity Study

Reuters
·
Dec 08, 2025

ASCLETIS-B (01672) Surges Over 4% as New Drug Denifanstat Tablet's Marketing Application Accepted

Stock News
·
Dec 08, 2025

Is Ascletis Pharma (SEHK:1672) Quietly Reframing Its Obesity Strategy With ASC37’s Oral Triple Agonist?

Simply Wall St.
·
Dec 07, 2025

Assessing Ascletis Pharma (SEHK:1672) Valuation After New ASC37 Obesity Candidate Advances Toward FDA IND Filing

Simply Wall St.
·
Dec 05, 2025

ASCLETIS-B (01672) Repurchases 1.62 Million Shares for HK$20.94 Million on December 4

Stock News
·
Dec 04, 2025

Ascletis Pharma Files HKEX Disclosure on Repurchase of 1.62 Million Shares for HK$20.94 Million

Reuters
·
Dec 04, 2025

HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%

Tiger Newspress
·
Dec 04, 2025

Hong Kong Stock Buyback Summary | December 4

Stock News
·
Dec 04, 2025

ASCLETIS-B (01672) Repurchased 1.306 Million Shares for HK$15.9275 Million on December 3

Stock News
·
Dec 03, 2025